tegafur has been researched along with Cholera Infantum in 17 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Here, we reported an interim analysis of feasibility and safety in the first 10 cases of 30 cases in a phase II trial of intravenous and intraperitoneal paclitaxel combined with S-1 for gemcitabine-refractory pancreatic cancer with malignant ascites." | 9.19 | Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. ( Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Uchino, R; Watanabe, T; Yamaguchi, H; Yamamoto, N; Yamashita, H, 2014) |
| "The combination of an oral fluoropyrimidine derivative, S-1, and irinotecan has been reported to be a promising regimen for advanced colorectal cancer." | 9.17 | Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer. ( Akashi, K; Arita, S; Baba, E; Esaki, T; Kishimoto, J; Kumagai, H; Kusaba, H; Mitsugi, K; Uchino, K, 2013) |
| "Here, we reported an interim analysis of feasibility and safety in the first 10 cases of 30 cases in a phase II trial of intravenous and intraperitoneal paclitaxel combined with S-1 for gemcitabine-refractory pancreatic cancer with malignant ascites." | 5.19 | Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. ( Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Uchino, R; Watanabe, T; Yamaguchi, H; Yamamoto, N; Yamashita, H, 2014) |
| "The combination of an oral fluoropyrimidine derivative, S-1, and irinotecan has been reported to be a promising regimen for advanced colorectal cancer." | 5.17 | Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer. ( Akashi, K; Arita, S; Baba, E; Esaki, T; Kishimoto, J; Kumagai, H; Kusaba, H; Mitsugi, K; Uchino, K, 2013) |
| "Twenty-five adult patients with adenocarcinoma of unknown primary origin were treated with oral tegafur followed by the combination of cyclophosphamide/adriamycin/cis-diamminedichloroplatinum(II) (CAP) if they failed to respond to tegafur." | 3.66 | Sequential chemotherapy for adenocarcinoma of unknown primary. ( Bedikian, AY; Bodey, GP; Burgess, MA; Valdivieso, M, 1983) |
| " The purpose of the current study was to identify which of the adverse events (AEs) contributed to the deterioration of QOL." | 2.82 | Identification of adverse events that have a negative impact on quality of life in a clinical trial comparing docetaxel versus S-1 with cisplatin in lung cancer. ( Aotani, E; Gemma, A; Hamano, T; Kobayashi, K; Takebayashi, T; Takeuchi, M, 2016) |
| "To test the efficacy and safety of pharmacokinetic modulating chemotherapy combined with cisplatin (PMC-cisplatin) as induction chemotherapy (ICT) before definitive treatment in patients with respectable locally advanced head and neck squamous cell carcinoma (HNSCC)." | 2.73 | Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study. ( Chang, PM; Chang, SY; Chen, PM; Chu, PY; Huang, JL; Tai, SK; Tsai, TL; Wang, LW; Wang, YF; Yang, MH, 2008) |
| " Pharmacokinetic data are consistent with potent modulation of 5-fluorouracil (5-FU) by CDHP, with prolonged half-life and 5-FU AUC at least 10-fold higher than reported in previous studies of equitoxic doses of tegafur modulated by uracil." | 2.70 | Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer. ( Beard, M; Cohen, SJ; Damle, B; DeCillis, AP; Leichman, CG; Letrent, SP; Meropol, NJ; Proefrock, A; Roedig, B; Yeslow, G, 2002) |
| " With regard to adverse events, the rates of nausea (p<0." | 1.42 | [A three-week regimen of S-1 monotherapy reduced gastrointestinal toxicity and maintained efficacy in patients with gemcitabine-refractory advanced pancreatic cancer]. ( Funazaki, H; Ikeda, M; Katayama, S; Kobayashi, M; Kondo, S; Kuwahara, A; Mitsunaga, S; Morizane, C; Ochiai, A; Ohno, I; Okusaka, T; Okuyama, H; Sakamoto, Y; Shimizu, S; Takahashi, H; Tanaka, H; Ueno, H, 2015) |
| " Gastrointestinal toxicity was evaluated by Common Toxicity Criteria for Adverse Events version 4." | 1.42 | Serum diamine oxidase activity as a predictor of gastrointestinal toxicity and malnutrition due to anticancer drugs. ( Fujino, Y; Goji, T; Kimura, T; Kitamura, S; Miyamoto, H; Miyoshi, J; Muguruma, N; Okahisa, T; Okamoto, K; Sogabe, M; Takayama, T; Taniguchi, T; Tomonari, T, 2015) |
| " on days 1-28, every 6 weeks) and assessed for all adverse events." | 1.35 | Safety evaluation of oral fluoropyrimidine S-1 for short- and long-term delivery in advanced gastric cancer: analysis of 3,758 patients. ( Fukushima, M; Ishiwata, R; Matsumoto, S; Nagai, Y; Teramukai, S; Yamanaka, T, 2008) |
| "A sample of 83 rectal cancer patients in Dukes' stages B2 or C who started a chemoradiotherapy treatment followed by surgery, have filled in the EORTC core questionnaire QLQC30 and the colorectal module QLQ-CR38, in three moments during the treatment and follow-up periods: at the beginning of the treatment, at the end of the chemoradiotherapy, and after surgery." | 1.33 | Quality of Life assessment through the EORTC questionnaires of locally advanced rectal cancer patients treated with preoperative chemo-radiotherapy. ( Arias de la Vega, F; Arraras Urdaniz, JI; Manterola Burgaleta, A; Martínez Aguillo, M; Salgado Pascual, E; Vera García, R; Villafranca Iturre, E, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.88) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Tsuchiya, T | 1 |
| Kamohara, R | 1 |
| Muraoka, M | 1 |
| Nagayasu, T | 1 |
| Saeki, S | 1 |
| Takenoyama, M | 1 |
| Suzuki, M | 1 |
| Inada, K | 1 |
| Tokunaga, S | 1 |
| Hayashi, T | 1 |
| Urabe, S | 1 |
| Koga, T | 1 |
| Akamine, S | 1 |
| Sugio, K | 1 |
| Takahara, N | 1 |
| Isayama, H | 1 |
| Nakai, Y | 1 |
| Sasaki, T | 1 |
| Ishigami, H | 1 |
| Yamashita, H | 1 |
| Yamaguchi, H | 1 |
| Hamada, T | 1 |
| Uchino, R | 1 |
| Mizuno, S | 1 |
| Miyabayashi, K | 1 |
| Mohri, D | 1 |
| Kawakubo, K | 1 |
| Kogure, H | 1 |
| Yamamoto, N | 1 |
| Sasahira, N | 1 |
| Hirano, K | 1 |
| Ijichi, H | 1 |
| Tateishi, K | 1 |
| Tada, M | 1 |
| Kitayama, J | 1 |
| Watanabe, T | 1 |
| Koike, K | 1 |
| Kajiwara, T | 1 |
| Miura, K | 1 |
| Ohnuma, S | 1 |
| Shimada, M | 1 |
| Komura, T | 1 |
| Toshima, M | 1 |
| Kohyama, A | 1 |
| Kudoh, K | 1 |
| Haneda, S | 1 |
| Musha, H | 1 |
| Naitoh, T | 1 |
| Shirasaka, T | 1 |
| Unno, M | 1 |
| Tanaka, H | 1 |
| Mitsunaga, S | 1 |
| Kobayashi, M | 1 |
| Funazaki, H | 1 |
| Katayama, S | 1 |
| Kuwahara, A | 1 |
| Okuyama, H | 1 |
| Takahashi, H | 1 |
| Ohno, I | 1 |
| Shimizu, S | 1 |
| Sakamoto, Y | 1 |
| Kondo, S | 1 |
| Morizane, C | 1 |
| Ueno, H | 1 |
| Okusaka, T | 1 |
| Ochiai, A | 1 |
| Ikeda, M | 1 |
| Miyoshi, J | 1 |
| Miyamoto, H | 1 |
| Goji, T | 1 |
| Taniguchi, T | 1 |
| Tomonari, T | 1 |
| Sogabe, M | 1 |
| Kimura, T | 1 |
| Kitamura, S | 1 |
| Okamoto, K | 1 |
| Fujino, Y | 1 |
| Muguruma, N | 1 |
| Okahisa, T | 1 |
| Takayama, T | 1 |
| Meulendijks, D | 1 |
| Henricks, LM | 1 |
| Sonke, GS | 1 |
| Deenen, MJ | 1 |
| Froehlich, TK | 1 |
| Amstutz, U | 1 |
| Largiadèr, CR | 1 |
| Jennings, BA | 1 |
| Marinaki, AM | 1 |
| Sanderson, JD | 1 |
| Kleibl, Z | 1 |
| Kleiblova, P | 1 |
| Schwab, M | 1 |
| Zanger, UM | 1 |
| Palles, C | 1 |
| Tomlinson, I | 1 |
| Gross, E | 1 |
| van Kuilenburg, AB | 1 |
| Punt, CJ | 1 |
| Koopman, M | 1 |
| Beijnen, JH | 1 |
| Cats, A | 1 |
| Schellens, JH | 1 |
| Aotani, E | 1 |
| Hamano, T | 1 |
| Gemma, A | 1 |
| Takeuchi, M | 1 |
| Takebayashi, T | 1 |
| Kobayashi, K | 1 |
| Choi, IS | 1 |
| Lee, KW | 1 |
| Kim, KH | 1 |
| Kim, YJ | 1 |
| Kim, JH | 1 |
| Lee, JS | 1 |
| Kusaba, H | 1 |
| Esaki, T | 1 |
| Kishimoto, J | 1 |
| Uchino, K | 1 |
| Arita, S | 1 |
| Kumagai, H | 1 |
| Mitsugi, K | 1 |
| Akashi, K | 1 |
| Baba, E | 1 |
| Cohen, SJ | 1 |
| Leichman, CG | 1 |
| Yeslow, G | 1 |
| Beard, M | 1 |
| Proefrock, A | 1 |
| Roedig, B | 1 |
| Damle, B | 1 |
| Letrent, SP | 1 |
| DeCillis, AP | 1 |
| Meropol, NJ | 1 |
| Arraras Urdaniz, JI | 1 |
| Arias de la Vega, F | 1 |
| Vera García, R | 1 |
| Manterola Burgaleta, A | 1 |
| Martínez Aguillo, M | 1 |
| Villafranca Iturre, E | 1 |
| Salgado Pascual, E | 1 |
| Yamanaka, T | 1 |
| Matsumoto, S | 1 |
| Teramukai, S | 1 |
| Ishiwata, R | 1 |
| Nagai, Y | 1 |
| Fukushima, M | 1 |
| Nakajo, A | 1 |
| Hokita, S | 1 |
| Ishigami, S | 1 |
| Miyazono, F | 1 |
| Etoh, T | 1 |
| Hamanoue, M | 1 |
| Maenohara, S | 1 |
| Iwashita, T | 1 |
| Komatsu, H | 1 |
| Satoh, K | 1 |
| Aridome, K | 1 |
| Morita, S | 1 |
| Natsugoe, S | 1 |
| Takiuchi, H | 1 |
| Nakano, S | 1 |
| Maehara, Y | 1 |
| Sakamoto, J | 1 |
| Aikou, T | 1 |
| Chang, PM | 1 |
| Chen, PM | 1 |
| Chu, PY | 1 |
| Wang, LW | 1 |
| Tai, SK | 1 |
| Tsai, TL | 1 |
| Huang, JL | 1 |
| Wang, YF | 1 |
| Chang, SY | 1 |
| Yang, MH | 1 |
| Vestermark, LW | 1 |
| Jacobsen, A | 1 |
| Qvortrup, C | 1 |
| Hansen, F | 1 |
| Bisgaard, C | 1 |
| Baatrup, G | 1 |
| Rasmussen, P | 1 |
| Pfeiffer, P | 1 |
| Bedikian, AY | 1 |
| Bodey, GP | 1 |
| Valdivieso, M | 1 |
| Burgess, MA | 1 |
| Ribas, A | 1 |
| Albanell, J | 1 |
| Solé-Calvo, LA | 1 |
| Gallardo, E | 1 |
| Bellmunt, J | 1 |
| Vera, R | 1 |
| Vidal, R | 1 |
| Carulla, J | 1 |
| Baselga, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Study of S-1 in Combination With Radiotherapy in Locally Advanced or Recurrent Gastric Cancer[NCT01291407] | Phase 1 | 27 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Phase II Study of Paclitaxel Liposome Plus S-1 as Neoadjuvant Chemotherapy for Advanced Gastric Cancer[NCT02163291] | Phase 2 | 30 participants (Anticipated) | Interventional | 2013-12-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for tegafur and Cholera Infantum
| Article | Year |
|---|---|
Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gas | 2015 |
10 trials available for tegafur and Cholera Infantum
| Article | Year |
|---|---|
A single-arm, phase 2 study of adjuvant chemotherapy with oral tegafur-uracil for pathologically lymphovascular invasion positive stage IA non-small cell lung cancer: LOGIK0602 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Carcinoma, Non-Small-Cell Lung; | 2020 |
Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis.
Topics: Adenocarcinoma; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Identification of adverse events that have a negative impact on quality of life in a clinical trial comparing docetaxel versus S-1 with cisplatin in lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Carcinoma, Non-Small-Cell Lung; Cisplatin | 2016 |
Three-weekly S-1 plus cisplatin chemotherapy as first-line treatment for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2010 |
Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Cu | 2002 |
A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer.
Topics: Adenocarcinoma; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Disease Pr | 2008 |
Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2008 |
Long-term results of a phase II trial of high-dose radiotherapy (60 Gy) and UFT/l-leucovorin in patients with non-resectable locally advanced rectal cancer (LARC).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2008 |
Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma.
Topics: Administration, Oral; Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Breast | 1998 |
6 other studies available for tegafur and Cholera Infantum
| Article | Year |
|---|---|
Gastrointestinal toxicities of 5-fluorouracil increase the proportion of regulatory T cells in intestinal tract: advantages of alternate-day S-1 administration.
Topics: Animals; Antimetabolites, Antineoplastic; Disease Models, Animal; Drug Combinations; Fluorouracil; G | 2015 |
[A three-week regimen of S-1 monotherapy reduced gastrointestinal toxicity and maintained efficacy in patients with gemcitabine-refractory advanced pancreatic cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Female; Gastrointest | 2015 |
Serum diamine oxidase activity as a predictor of gastrointestinal toxicity and malnutrition due to anticancer drugs.
Topics: Adult; Aged; Amine Oxidase (Copper-Containing); Antineoplastic Agents; Antineoplastic Combined Chemo | 2015 |
Quality of Life assessment through the EORTC questionnaires of locally advanced rectal cancer patients treated with preoperative chemo-radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Image; Emotions | 2006 |
Safety evaluation of oral fluoropyrimidine S-1 for short- and long-term delivery in advanced gastric cancer: analysis of 3,758 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Cohort Studies; Drug Combin | 2008 |
Sequential chemotherapy for adenocarcinoma of unknown primary.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 1983 |